IceCure Medical Ltd. has encountered a significant hurdle in its efforts to secure a permanent Current Procedural Terminology (CPT) category I code for its ProSense system. The American Medical Association (AMA) recently announced that it will not approve the company's request, which is crucial for the reimbursement of its cryoablation procedure used in treating cancerous breast tumors.

The AMA's decision, published on October 2, 2026, follows a review during its September 2026 CPT Editorial Panel meeting. IceCure, along with supporting medical societies, had advocated for the transition from the existing CPT category III code to a permanent category I code. However, the AMA deemed the request premature, indicating that IceCure needs to continue expanding its clinical evidence and increasing utilization of its ProSense system.

This setback means that IceCure will continue operating under the temporary CPT category III code, which allows facilities to receive approximately $4,000 for the facility fee associated with the ProSense procedure. The company maintains its ability to conduct commercial activities under this existing reimbursement framework with the Centers for Medicare and Medicaid Services (CMS).

IceCure Medical Ltd. is a company focused on developing innovative medical technologies, particularly in the field of surgical and medical instruments and apparatus. The company trades under the ticker ICCM on the Nasdaq exchange and is categorized as an emerging growth company.

The AMA's decision does not affect IceCure's current reimbursement status but does highlight the challenges the company faces in gaining broader acceptance for its technology. The company plans to resubmit its application for a CPT category I code in June 2027, allowing it additional time to bolster its clinical evidence.

As the industry watches closely, IceCure's competitors in the surgical and medical instruments sector may also be impacted by this decision. The ongoing developments in reimbursement policies and coding will be critical for all players in this space.

The next steps for IceCure involve continuing to gather clinical evidence and working with leading medical societies to prepare for the resubmission of their CPT category I code request.